{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:37:02Z","timestamp":1795095422281,"version":"4.10.2"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To assess the risk of recurrence of breast cancer associated with vaginal estrogen therapy in women diagnosed with genitourinary syndrome of menopause with a history of breast cancer using a large U.S. claims database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      A U.S. health research network (TriNetX Diamond Network) was queried from January 2009 to June 2022. Our cohort consisted of women diagnosed with breast cancer within 5 years before the initial genitourinary syndrome of menopause diagnosis. Patients with\n                      <jats:italic toggle=\"yes\">active disease<\/jats:italic>\n                      , defined as those undergoing mastectomy, radiation treatment, or chemotherapy within 3 months before diagnosis of genitourinary syndrome of menopause, were excluded.\n                      <jats:italic toggle=\"yes\">Recurrence<\/jats:italic>\n                      was defined as mastectomy, radiation, chemotherapy, or secondary malignancy within 3 months to 5 years after the initiation of vaginal estrogen therapy for genitourinary syndrome of menopause. The study cohort included those with three or more vaginal estrogen prescriptions. The control cohort included women with breast cancer without any vaginal estrogen prescriptions after genitourinary syndrome of menopause diagnosis. Propensity matching was performed. A subanalysis by positive estrogen receptor status, when available, was performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>We identified 42,113 women with a diagnosis of genitourinary syndrome of menopause after breast cancer diagnosis with any estrogen receptor status, 5.0% of whom received vaginal estrogen. Of the initial cohort, 10,584 patients had a history of positive estrogen receptor breast cancer, and 3.9% of this group received vaginal estrogen. Risk of breast cancer recurrence was comparable between those who received vaginal estrogen and those who did not in both the any estrogen receptor (risk ratio 1.03, 95% CI 0.91\u20131.18) and positive estrogen receptor (risk ratio 0.94, 95% CI 0.77\u20131.15) status analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>In a large, claims-based analysis, we did not find an increased risk of breast cancer recurrence within 5 years in women with a personal history of breast cancer who were using vaginal estrogen for genitourinary syndrome of menopause.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005294","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T18:37:52Z","timestamp":1691087872000},"page":"660-668","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":54,"title":["Safety of Vaginal Estrogen Therapy for Genitourinary Syndrome of Menopause in Women With a History of Breast Cancer"],"prefix":"10.1097","volume":"142","author":[{"given":"Pranjal","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajya M.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Able","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaden","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor P.","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Clifton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5306\/wjco.v13.i2.71","article-title":"Management of genitourinary syndrome of menopause in breast cancer survivors: an update","volume":"13","author":"L\u00f3pez","year":"2022","journal-title":"World J Clin Oncol"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clbc.2015.06.005","article-title":"Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe hopes?","volume":"15","author":"Biglia","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"R4-20260916","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/PPO.0000000000000598","article-title":"Individual benefits and risks of intravaginal estrogen and systemic testosterone in the management of women in the menopause, with a discussion of any associated risks for cancer development","volume":"28","author":"Laing","year":"2022","journal-title":"Cancer J"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.maturitas.2020.08.010","article-title":"Genitourinary syndrome of menopause: current treatment options in breast cancer survivors: systematic review","volume":"143","author":"Mension","year":"2021","journal-title":"Maturitas"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/GME.0000000000001221","article-title":"A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause","volume":"26","author":"Biehl","year":"2019","journal-title":"Menopause"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/GME.0000000000001121","article-title":"Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American Menopause Society and the International Society for the Study of Women's Sexual Health","volume":"25","author":"Faubion","year":"2018","journal-title":"Menopause"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10549-022-06812-z","article-title":"Estimating the incidence of breast cancer recurrence using administrative data","volume":"198","author":"Habbous","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jnci\/djx200","article-title":"Development, validation, and dissemination of a breast cancer recurrence detection and timing informatics algorithm","volume":"110","author":"Ritzwoller","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"R10-20260916","first-page":"1179","article-title":"Sexual concerns in cancer patients: a comparison of GI and breast cancer patients","volume":"18","author":"Reese","year":"2010","journal-title":"Support Care Cancer"},{"key":"R11-20260916","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12885-015-1243-8","article-title":"Perceived causes and consequences of sexual changes after cancer for women and men: a mixed method study","volume":"15","author":"Ussher","year":"2015","journal-title":"BMC Cancer"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djac112","article-title":"Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study","volume":"114","author":"Cold","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/01.gme.0000227401.98933.0b","article-title":"A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women","volume":"13","author":"Long","year":"2006","journal-title":"Menopause"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/nau.23977","article-title":"Effects of topical estrogen therapy on the vaginal microcirculation in women with vulvovaginal atrophy","volume":"38","author":"Diedrich","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"R16-20260916","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.clbc.2017.05.008","article-title":"Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists","volume":"17","author":"Biglia","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"R18-20260916","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/j.clbc.2019.07.007","article-title":"The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis","volume":"19","author":"Pavlovi\u0107","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"R19-20260916","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/GME.0000000000001079","article-title":"Vaginal estrogen and mammogram results: case series and review of literature on treatment of genitourinary syndrome of menopause (GSM) in breast cancer survivors","volume":"25","author":"Zuo","year":"2018","journal-title":"Menopause"},{"key":"R20-20260916","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study","volume":"135","author":"Le Ray","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"R21-20260916","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/13697137.2021.1891218","article-title":"Sustainability of vaginal estrogens for genitourinary syndrome of menopause: a systematic review","volume":"24","author":"Weidlinger","year":"2021","journal-title":"Climacteric"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:05:10Z","timestamp":1789556710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005294","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"2023-02-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}